Details
Nearly 40% of patients with AL amyloidosis wait more than a year for a diagnosis.
By the time many are referred, the heart is already silently, irreversibly damaged. And we know what that means for survival.
Here is what the new BSH guideline (Garg et al., Br J Haematol 2026) wants every haematologist to know:
Stage determines everything.
Early disease carries ~80% 5-year survival with modern therapy.
Stage IIIc — NT-proBNP >8500 ng/L, TnT ≥0.035 mcg/L, GLS >-9% — carries a median survival of just 4 months. That gap is almost entirely explained by diagnostic delay.